Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Inspire Pharmaceuticals (NasdaqNM:ISPH)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Financials
Recent Events
Aug  7Earnings Announcement
Location
4222 Emperor Boulevard, Suite 470
Durham, NC 27703
Phone: (919) 941-9777
Fax: (919) 941-9797
Email: info@inspirepharm.com
Employees (last reported count): 37
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 50%
·Over the last 6 months:
 · one insider buy; 5,000  shares
 · 6 insider sells; 267.0K shares
  (2.0% of insider shares)
·Institutional: 35% (69% of float)
(87 institutions)
·Net Inst. Buying: 2.40M shares (+21.24%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Inspire Pharmaceuticals, Inc. discovers and develops new drugs, or pharmaceutical products, to treat diseases characterized by deficiencies in the body's innate defense mechanisms of mucosal hydration and mucociliary clearance, as well as other non-mucosal disorders. The Company's products are based on its proprietary technology relating to P2Y receptors. Studies indicate that a subtype of this family, the P2Y2 receptor, coordinates the mechanisms of mucosal hydration and mucociliary clearance. These complex mechanisms, which involve movement of salt and water, a protein substance made in specialized cells that act to lubricate surfaces, called mucin and the movement of cilia, or hairlike projections on the surface of cells that move together in a sweeping motion to move liquid and particles forward, can be regulated therapeutically through the stimulation of this receptor. Its lead products target respiratory and ophthalmic diseases with few current treatments.
More from Market Guide: Expanded Business Description

Financial Summary
Inspire Pharmaceuticals, Inc. is engaged in the research and development efforts related to the P2Y\\2\\ receptor, which coordinates the body's innate defense mechanisms of mucosal hydration and mucociliary clearance. For the six months ended 6/30/01, revenues rose 22% to $2.8 million. Net loss applicable to Com. totaled $11.1 million, up from $5.5 million. Results reflect the up-front payment from Kirin Brewery, offset by increased expense for drug development activities.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

Terrance McGuire, 45
Chairman
--  --  
Christy Shaffer, Ph.D, 43
Pres, CEO, Director
$273K$503K
Gregory Mossinghoff, 40
Sr. VP, Sec., Treasurer and CBO, Director
235K--  
Donald Kellerman, 46
Sr. VP, Devel.
221K--  
Mary Bennett, 43
VP-Operations and Communications
--  --  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:ISPHAs of 31-Aug-2001
Price and Volume
52-Week Low
on 21-Mar-2001
$5.875
Recent Price$10.97 
52-Week High
on 7-Nov-2000
$31.75 
Daily Volume (3-month avg)107.8K
Daily Volume (10-day avg)39.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y]
52-Week Change-36.6%
52-Week Change
relative to S&P500
-15.0%
Share-Related Items
Market Capitalization$282.3M
Shares Outstanding25.7M
Float12.9M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$2.49 
Earnings (ttm)-$0.88 
Earnings (mrq)-$0.23 
Sales (ttm)$0.25 
Cash (mrq)$2.67 
Valuation Ratios
Price/Book (mrq)4.41 
Price/EarningsN/A 
Price/Sales (ttm)43.80 
Income Statements
Sales (ttm)$5.87M
EBITDA (ttm)-$21.7M
Income available to common (ttm)-$20.2M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-29.41%
Return on Equity (ttm)-40.29%
Financial Strength
Current Ratio (mrq)8.02 
Debt/Equity (mrq)0.02 
Total Cash (mrq)$68.8M
Short Interest
As of 8-Aug-2001
Shares Short246.0K
Percent of Float1.9%
Shares Short
(Prior Month)
432.0K
Short Ratio4.47 
Daily Volume55.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.